Salute e Benessere

OXURION : Postponement Annual Shareholders Meeting

Leuven, BELGIUM – April 7, 2026 – 18:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a pharmaceutical outsourcing company based in Leuven, today made the following announcement regarding the financial calendar: Due to administrative reasons, the annual accounts of the Company have not been finalized yet…
Actusnews Wire
07/04/2026

Klea Holding is accelerating its diversification into the healthcare sector with…

Paris, 1 April 2026 KLEA HOLDING (FR0013481835 – ALKLH), a group specialising in the acquisition, development and digitalisation of businesses across various sectors, announces the creation of Klea Pharmaceuticals, a new company set up to market a portfolio of licensed medicines in high-growth markets across the Middle East and Africa…
Actusnews Wire
01/04/2026

DMS GROUP: THE EUROPEAN INVESTMENT BANK GRANTS A FINANCING LINE OF UP TO EUR 20…

Funding with the support of the European Union, through InvestEU, to accelerate the development of the new generation of medical imaging solutions as part of the next strategic plan #Imaging 2030 with the ambition to make DMS Group a European leader in medical imaging on the world stage. The financing is part of EIB's strong commitment to health…
Actusnews Wire
27/03/2026

THERANEXUS : THX Pharma Announces the Publication of its Letter to Shareholders

Lyon, France – March 25, 2026, 6:30 pm CET – THX Pharma (Theranexus), an innovative biopharmaceutical company in the treatment of rare neurological diseases, today announces the publication of its letter to shareholders. To download the newsletter, click here. This letter is also available on the Theranexus website (link), in the…
Actusnews Wire
25/03/2026

Oxurion signs a letter of intent for the acquisition of an international CRO

Leuven, BELGIUM – March 19, 2026 – 18:30 PM CET - Oxurion NV (Euronext Brussels: OXUR), a pharmaceutical outsourcing company based in Leuven, announces the signing of a letter of intent (LOI) for the acquisition of a majority stake in an international CRO operating in Europe, North Africa, and the Middle East…
Actusnews Wire
19/03/2026

Oxurion ondertekent een intentieverklaring voor de overname van een…

Leuven, BELGIË – 19 maart 2026 – 18u30 CET Oxurion NV (Euronext Brussel: OXUR), een farmaceutische onderaannemingsvennootschap gevestigd in Leuven, kondigt de ondertekening aan van een intentieverklaring (LOI) voor de overname van een meerderheidsbelang in een internationale CRO die actief is in Europa, Noord-Afrika en het Midden-Oosten…
Actusnews Wire
19/03/2026

BASTIDE : 2025-2026 half-year results

Recurring operating margin: 9.0%, in line with the annual target Operating profit up 12.5% Operating free cash flow: €24.3 million, a threefold increase in one year Significant improvement in leverage: 2.77x at December 31, 2025 (vs 3.41x at June 30, 2025) 2025-2026 outlook confirmed Caissargues, March 18, 2026 – Groupe Bastide, a leading European…
Actusnews Wire
18/03/2026

Oxurion Receives Transparency Notification from Atlas Special Opportunities II…

Leuven, BELGIUM – March 18, 2026 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows: Oxurion received a transparency notification on March 17, 2026, from Atlas Special Opportunities II…
Actusnews Wire
18/03/2026

OXURION : Information on the Total Number of Voting Rights (Denominator)…

Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment[1]. Leuven, BELGIUM – March 16 2026 – 06:00 PM CET – In accordance with article 15 of the Belgian Act of May 2, 2007 on the disclosure of…
Actusnews Wire
16/03/2026

ATON: UPDATE ON THE ACTIVITIES OF ITS SUBSIDIARY INOVIEM SCIENTIFIC

Illkirch, March 11th 2026 – 18h00 Aton Group (Euronext Growth Paris – FR0004153930 – ALTAO), a life sciences and medtech investment holding, provides an update on the operational activities of its subsidiary Inoviem Scientific (the “Company”), a translational pharmacology company. Inoviem Scientific is reimagining drug development and deployment by…
Actusnews Wire
11/03/2026

Oxurion verlengt haar financieringsprogramma

Leuven, BELGIË – 10 maart 2026 – 18u30 CET Oxurion NV (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf met hoofdzetel in Leuven, kondigt de ondertekening aan van een vierde amendement op haar converteerbare obligatie-intekeningsovereenkomst met Atlas Special Opportunities II, LLC. Dit amendement verlengt het totale financieringsprogramma met…
Actusnews Wire
10/03/2026

Oxurion Extends Its Financing Program

Leuven, BELGIUM – March 10, 2026 – 06:30 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, announces the signing of a fourth amendment to its convertible bond subscription agreement with Atlas Special Opportunities II, LLC. This amendment extends the overall financing program by an additional 12…
Actusnews Wire
10/03/2026

LUMIBIRD : 2025 ANNUAL RESULTS SHOW STRONG GROWTH

Lannion, 10/03/2026 – 5:45 pm 2025 annual results show strong growth EBITDA margin(1) of 20.2%, up +4.3 points Free cash flow of €13.1 million Implementation of a dividend distribution The Lumibird Group, European leader in laser technologies, recorded strong growth in its results in 2025, with EBITDA of €45.6 million, up +38% and representing 20…
Actusnews Wire
10/03/2026

Oxurion bevestigt voortzetting van de besprekingen over haar voorgenomen…

Leuven, BELGIUM– 27 februari 2026 – 18u00 CET –Oxurion NV (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf met hoofdkantoor in Leuven, kondigt de verlenging aan van de onderhandelingen met betrekking tot de voorgenomen verwerving van een meerderheidsbelang in een Franse CRO, zoals aangekondigd op 13 oktober 2025…
Actusnews Wire
27/02/2026

Oxurion confirms continuation of discussions regarding its proposed acquisition…

Leuven, BELGIUM – 27 februari 2026 – 06:00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, announces the extension of the negotiations relating to the proposed acquisition of a majority stake in a French CRO, as previously announced on 13 October 2025…
Actusnews Wire
27/02/2026

Oxurion Receives Transparency Notification from Atlas Special Opportunities II…

Leuven, BELGIUM – February 25, 2026 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows: Oxurion received a transparency notification on February 23, 2026, from Atlas Special Opportunities…
Actusnews Wire
25/02/2026

Oxurion Receives Transparency Notification from Atlas Special Opportunities II…

Leuven, BELGIUM – February 19, 2026 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows: Oxurion received a transparency notification on February 18, 2026, from Atlas Special Opportunities…
Actusnews Wire
19/02/2026

THERANEXUS : THX Pharma Reports Its Cash Position as of December 31, 2025

Lyon, France – February 19, 2026, 6:00 p.m. CET – THX Pharma (Theranexus), an innovative biopharmaceutical company specializing in the treatment of rare neurological diseases, today announces the publication of its cash position as of December 31, 2025. As of December 31, 2025, available cash amounted to €7,764 thousand, compared with €1,979…
Actusnews Wire
19/02/2026

ATON APPOINTS HADRIEN LANVIN AS DEPUTY CEO

Illkirch, February 18, 2026 – 6.30 pm Aton Group (Euronext Growth Paris - FR0004153930 - ALTAO), a leader in life sciences and medical technology, today announced the appointment of Hadrien Lanvin as Deputy Chief Executive Officer. Alumnus of HEC Paris, Hadrien Lanvin is the Founder and CEO of biotechnology firm Evora Biosciences…
Actusnews Wire
18/02/2026

Playful Nordic design – what is the secret formula?

Industrial News Service
16/02/2026

OXURION : Axiodis CRO accelerates its sales and marketing strategy to support…

Toulouse, France – February 16, 2026 – 8:00 a.m. Axiodis CRO, a subsidiary of the Oxurion Group (Euronext Brussels: OXUR) specializing in clinical data management, announces a major milestone in the implementation of its development strategy: the recruitment of its first dedicated sales representative and a marketing manager, in addition to the…
Actusnews Wire
16/02/2026

OXURION : Axiodis CRO versnelt zijn commerciële en marketingstrategie om…

Toulouse, Frankrijk – 16 februari 2026 – 08h00. Axiodis CRO, een dochteronderneming van de Oxurion-groep (Euronext Brussel: OXUR), gespecialiseerd in het beheer van klinische gegevens, kondigt een belangrijke stap aan in de uitvoering van haar ontwikkelingsstrategie: de aanwerving van een eerste toegewijde salesmedewerker en een marketingmanager…
Actusnews Wire
16/02/2026

BASTIDE : Organic growth of 8.2% in first-half 2025-2026: Confirmed excellent…

Caissargues, February 12, 2026 – Groupe Bastide, a leading European provider of home healthcare services, has published its revenue for first-half 2025-2026, ending December 31, 2025. In € millions 2024-2025 published 2024-2025 restated* 2025-2026 published Change First-quarter revenue 133.8 116.9 126.3 +8.0% Second-quarter revenue 141.5 124.1 134…
Actusnews Wire
12/02/2026

THERANEXUS : THX Pharma to Host a Webinar to Discuss Its Strategic Agreement…

THX Pharma to Host a Webinar to Discuss Its Strategic Agreement with Biocodex Lyon, France – February 12, 2026 – 6:00 p.m. CET – THX Pharma (Theranexus), an innovative biopharmaceutical company focused on the treatment of rare neurological diseases, announces that it will host a live webinar on Tuesday, February 17 at 6:00 p.m…
Actusnews Wire
12/02/2026
Altri  Comunicati